Am J Med Genet A 158A(10):2519–2525PubMedCrossRef Universal Declaration on the Human Genome and Human Rights (1997) UNESCO. http://portal.unesco.org/en/ev.php-URL_ID=13177&URL_DO=DO_TOPIC&URL_SECTION=201.html. PI3K inhibitor Accessed 18 Dec 2013 van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, Howard HC, Cambon-Thomsen A, Knoppers BM, Meijers-Heijboer H,
Scheffer H, Tranebjaerg L, Dondorp W, de Wert GM, Public E, Professional Policy C (2013a) Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet 21(Suppl 1):S1–S5PubMedCentralPubMed van El CG, Dondorp WJ, de Wert GMWR, Cornel MC (2013b) Call for prudence in whole-genome testing. Science BAY 11-7082 in vivo 341(6149):958–959PubMed Wilson BJ, Forrest K, van Teijlingen ER, McKee L, Haites N, Matthews E, Simpson SA (2004) Family communication about genetic risk: the little that is known. Community Genet 7(1):15–24PubMedCrossRef Wimmer
RD, Dominick JR (2011) Mass media research: an introduction, Ninth edition. Wadsworth – Cengage Learning Canada Wolf SM, Paradise J, Caga-anan C (2008) The law of incidental findings in human Combretastatin A4 nmr subjects research: establishing researchers’ duties. J Law Med Ethics 36(2):361–383, 214PubMedCentralPubMedCrossRef Wright CF, Middleton A, Burton H, Cunningham F, Humphries SE, Hurst J, Birney E, Firth HV (2013) Policy challenges of clinical genome sequencing. BMJ (Clin Res Ed) 347:f6845 Yang LH, Purdie-Vaughns V, Kotabe H, Link BG, Saw A, Wong G, Phelan JC (2013) Culture, threat, and mental illness stigma: identifying culture-specific threat among Chinese-American groups. Soc Sci Med (1982) 88:56–67CrossRef
Zawati MH, Knoppers BM (2012) International normative perspectives on the return of individual research results and Mirabegron incidental findings in genomic biobanks. Genet Med 14(4):484–489PubMedCrossRef”
“Breast cancer is a significant health concern for African American women, with more than 26,000 of these women diagnosed every year (The Breast Cancer Linkage Consortium 1999). BRCA1/2 gene mutations account for approximately 10 % of breast and ovarian cancer cases, and confer an estimated range from 40–60 % lifetime risk of developing invasive breast cancer, and a 20–40 % lifetime risk for invasive ovarian cancer (Cancer Institute NSW 2013a, 2013b). Similar rates of BRCA1 and BRCA2 mutations have been identified in African American and Caucasian populations, although the spectrum of mutations of risk among ethnic minorities are not completely defined (Olopade et al. 2003; Shen et al. 2000; Pal et al. 2004; Gao et al. 2000; Armstrong et al. 2005; Hall and Olopade 2006; Hughes et al. 2004; Nanda et al. 2005).